Loading...

TherapeuticsMD

Nasdaq:TXMD
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TXMD
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

TherapeuticsMD, Inc. operates as a women’s health care product company in the United States. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
  • TherapeuticsMD has significant price volatility in the past 3 months.
TXMD Share Price and Events
7 Day Returns
-1.3%
NasdaqGS:TXMD
1%
US Pharmaceuticals
2.9%
US Market
1 Year Returns
5.2%
NasdaqGS:TXMD
8.3%
US Pharmaceuticals
1.4%
US Market
TXMD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TherapeuticsMD (TXMD) -1.3% -3.4% 51.2% 5.2% -12.9% -17.1%
US Pharmaceuticals 1% 1.7% 2.8% 8.3% 19.1% 20.1%
US Market 2.9% 2.5% 10% 1.4% 38.3% 42%
1 Year Return vs Industry and Market
  • TXMD underperformed the Pharmaceuticals industry which returned 8.3% over the past year.
  • TXMD outperformed the Market in United States of America which returned 1.4% over the past year.
Price Volatility
TXMD
Industry
5yr Volatility vs Market

Value

 Is TherapeuticsMD undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of TherapeuticsMD to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our intrinsic value calculation method has changed recently, learn more here.

Below are the data sources, inputs and calculation used to determine the intrinsic value for TherapeuticsMD.

NasdaqGS:TXMD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:TXMD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.68 (1 + (1- 21%) (5.57%))
0.806
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.806 * 5.96%)
7.53%

Discounted Cash Flow Calculation for NasdaqGS:TXMD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for TherapeuticsMD is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:TXMD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.53%)
2019 -161.07 Analyst x3 -149.79
2020 -15.93 Analyst x3 -13.78
2021 128.55 Analyst x4 103.39
2022 383.58 Analyst x5 286.88
2023 338.87 Analyst x3 235.69
2024 312.26 Est @ -7.85% 201.97
2025 297.66 Est @ -4.68% 179.04
2026 290.35 Est @ -2.45% 162.41
2027 287.74 Est @ -0.9% 149.68
2028 288.28 Est @ 0.19% 139.46
Present value of next 10 years cash flows $1,294.96
NasdaqGS:TXMD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $288.28 × (1 + 2.73%) ÷ (7.53% – 2.73%)
$6,167.37
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $6,167.37 ÷ (1 + 7.53%)10
$2,983.51
NasdaqGS:TXMD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,294.96 + $2,983.51
$4,278.46
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,278.46 / 241.16
$17.74
NasdaqGS:TXMD Discount to Share Price
Calculation Result
Value per share (USD) From above. $17.74
Current discount Discount to share price of $5.46
= -1 x ($5.46 - $17.74) / $17.74
69.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price TherapeuticsMD is available for.
Intrinsic value
>50%
Share price is $5.46 vs Future cash flow value of $17.74
Current Discount Checks
For TherapeuticsMD to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • TherapeuticsMD's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • TherapeuticsMD's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TherapeuticsMD's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TherapeuticsMD's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:TXMD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.59
NasdaqGS:TXMD Share Price ** NasdaqGS (2019-03-15) in USD $5.46
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.34x
United States of America Market PE Ratio Median Figure of 3,054 Publicly-Listed Companies 17.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TherapeuticsMD.

NasdaqGS:TXMD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:TXMD Share Price ÷ EPS (both in USD)

= 5.46 ÷ -0.59

-9.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TherapeuticsMD is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • TherapeuticsMD is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does TherapeuticsMD's expected growth come at a high price?
Raw Data
NasdaqGS:TXMD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
60.4%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 1.51x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.47x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for TherapeuticsMD, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on TherapeuticsMD's assets?
Raw Data
NasdaqGS:TXMD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.41
NasdaqGS:TXMD Share Price * NasdaqGS (2019-03-15) in USD $5.46
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 178 Publicly-Listed Pharmaceuticals Companies 3.41x
United States of America Market PB Ratio Median Figure of 5,152 Publicly-Listed Companies 1.87x
NasdaqGS:TXMD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:TXMD Share Price ÷ Book Value per Share (both in USD)

= 5.46 ÷ 0.41

13.46x

* Primary Listing of TherapeuticsMD.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TherapeuticsMD is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess TherapeuticsMD's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. TherapeuticsMD has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is TherapeuticsMD expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
60.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TherapeuticsMD expected to grow at an attractive rate?
  • TherapeuticsMD's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • TherapeuticsMD's earnings growth is expected to exceed the United States of America market average.
  • TherapeuticsMD's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:TXMD Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:TXMD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 60.4%
NasdaqGS:TXMD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 47.2%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.5%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:TXMD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:TXMD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 881 375 384 5
2022-12-31 670 292 298 5
2021-12-31 436 136 135 6
2020-12-31 227 -30 -47 6
2019-12-31 48 -146 -158 6
NasdaqGS:TXMD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 16 -107 -133
2018-09-30 15 -99 -115
2018-06-30 16 -82 -94
2018-03-31 17 -75 -80
2017-12-31 17 -76 -77
2017-09-30 17 -71 -78
2017-06-30 18 -73 -89
2017-03-31 18 -70 -90
2016-12-31 19 -69 -90
2016-09-30 20 -70 -85
2016-06-30 20 -70 -79
2016-03-31 21 -79 -85

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • TherapeuticsMD's earnings are expected to grow significantly at over 20% yearly.
  • TherapeuticsMD's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:TXMD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from TherapeuticsMD Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:TXMD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.46 2.08 0.94 4.00
2022-12-31 1.15 1.37 0.98 4.00
2021-12-31 0.52 0.68 0.35 5.00
2020-12-31 -0.07 0.25 -0.30 5.00
2019-12-31 -0.66 -0.61 -0.75 5.00
NasdaqGS:TXMD Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.59
2018-09-30 -0.52
2018-06-30 -0.44
2018-03-31 -0.38
2017-12-31 -0.37
2017-09-30 -0.39
2017-06-30 -0.45
2017-03-31 -0.46
2016-12-31 -0.46
2016-09-30 -0.44
2016-06-30 -0.42
2016-03-31 -0.47

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if TherapeuticsMD will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess TherapeuticsMD's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TherapeuticsMD has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has TherapeuticsMD performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TherapeuticsMD's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TherapeuticsMD does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare TherapeuticsMD's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare TherapeuticsMD's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
TherapeuticsMD's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TherapeuticsMD Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:TXMD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 16.10 -132.62 115.99 27.30
2018-09-30 15.13 -114.65 94.76 31.52
2018-06-30 16.08 -93.71 76.46 31.25
2018-03-31 16.57 -80.17 61.62 33.17
2017-12-31 16.78 -76.93 57.70 33.85
2017-09-30 17.14 -78.33 59.85 33.22
2017-06-30 18.26 -88.69 62.52 41.45
2017-03-31 18.41 -90.10 58.51 46.57
2016-12-31 19.36 -89.88 51.35 53.94
2016-09-30 20.50 -84.52 43.65 56.86
2016-06-30 20.15 -78.98 35.99 58.61
2016-03-31 20.60 -85.11 32.24 68.96
2015-12-31 20.14 -85.08 28.72 72.04
2015-09-30 18.77 -83.90 25.60 72.96
2015-06-30 17.77 -82.26 24.59 71.44
2015-03-31 16.67 -65.93 23.26 55.49
2014-12-31 15.03 -54.22 22.12 43.22
2014-09-30 13.63 -46.29 21.17 34.89
2014-06-30 11.74 -36.12 19.58 24.38
2014-03-31 10.07 -31.23 19.52 17.89
2013-12-31 8.78 -28.42 19.01 13.55
2013-09-30 7.15 -25.77 19.39 9.07
2013-06-30 5.90 -22.37 17.67 6.56
2013-03-31 4.63 -28.21 15.77 5.65
2012-12-31 3.82 -35.12 14.07 4.49
2012-09-30 3.13 -38.98 11.73 2.98
2012-06-30 2.63 -36.21 10.62 1.19
2012-03-31 2.32 -25.43 8.25 0.46

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if TherapeuticsMD has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if TherapeuticsMD has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if TherapeuticsMD improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess TherapeuticsMD's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TherapeuticsMD has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is TherapeuticsMD's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TherapeuticsMD's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TherapeuticsMD is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • TherapeuticsMD's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TherapeuticsMD's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TherapeuticsMD Company Filings, last reported 2 months ago.

NasdaqGS:TXMD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 97.52 73.38 161.61
2018-09-30 134.22 73.26 190.00
2018-06-30 77.55 73.14 154.39
2018-03-31 107.30 0.00 107.35
2017-12-31 129.91 0.00 127.14
2017-09-30 149.48 0.00 148.29
2017-06-30 93.59 0.00 96.48
2017-03-31 110.33 0.00 113.53
2016-12-31 127.49 0.00 131.53
2016-09-30 146.35 0.00 147.53
2016-06-30 167.25 0.00 166.53
2016-03-31 183.37 0.00 182.10
2015-12-31 63.06 0.00 64.71
2015-09-30 77.56 0.00 81.12
2015-06-30 63.01 0.00 67.25
2015-03-31 87.72 0.00 91.66
2014-12-31 48.39 0.00 51.36
2014-09-30 63.60 0.00 67.00
2014-06-30 37.48 0.00 35.55
2014-03-31 46.75 0.00 45.40
2013-12-31 54.70 0.00 54.19
2013-09-30 62.09 0.00 59.57
2013-06-30 38.47 0.00 34.44
2013-03-31 39.94 0.10 38.78
2012-12-31 -1.43 3.59 1.55
2012-09-30 -4.33 5.59 0.15
2012-06-30 -0.70 3.54 1.33
2012-03-31 -3.35 3.76 0.20
  • TherapeuticsMD's level of debt (75.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 75.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • TherapeuticsMD has sufficient cash runway for 1.3 years based on current free cash flow.
  • TherapeuticsMD has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 15.2% each year.
X
Financial health checks
We assess TherapeuticsMD's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TherapeuticsMD has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is TherapeuticsMD's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from TherapeuticsMD dividends.
If you bought $2,000 of TherapeuticsMD shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate TherapeuticsMD's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate TherapeuticsMD's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:TXMD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:TXMD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as TherapeuticsMD has not reported any payouts.
  • Unable to verify if TherapeuticsMD's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of TherapeuticsMD's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as TherapeuticsMD has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess TherapeuticsMD's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TherapeuticsMD afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TherapeuticsMD has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of TherapeuticsMD's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rob Finizio
COMPENSATION $2,983,955
AGE 47
TENURE AS CEO 7.4 years
CEO Bio

Mr. Robert G. Finizio, also known as Rob, is the Co-Founder of TherapeuticsMD, Inc. and has been its Chief Executive Officer since October 4, 2011. Mr. Finizio served as the Principal Accounting Officer of TherapeuticsMD, Inc. As co-founder of VitaMed, from April 2008 to October 4, 2011 Mr. Finizio served as its Chief Executive Officer. From August 2001 to February 2008, he co-founded and served as President of Care Fusion, LLC. Mr. Finizio co-founded Care Fusion, Inc. in 2001 and served as its Vice President of Business Development and Chief Executive Officer. He was responsible for overseeing strategic initiatives and corporate partnerships of Care Fusion, Inc. He has over 10 years of experience in healthcare and healthcare informatics. Mr. Finizio has extensive experience with commercial and government contracting and large-scale account management. He served as Regional Sales Manager and Sales Director of Omnicell, where he sold enterprise scale clinical workflow solutions. Mr. Finizio worked in sales and sales management for Endoscopy Specialists Inc. He served as the Chairman of the Board of Vitamed and TherapeuticsMD, Inc. since October 4, 2011. He has been a Director of TherapeuticsMD, Inc. since October 4, 2011. He served as a Director of Vitamed from April 2008 to October 2011. A member of HIMSS, Mr. Finizio earned a Bachelor of Science degree in Pre-Med from the University of Miami in Coral Gables, FL.

CEO Compensation
  • Rob's compensation has increased whilst company is loss making.
  • Rob's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the TherapeuticsMD management team in years:

6.7
Average Tenure
51
Average Age
  • The average tenure for the TherapeuticsMD management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Rob Finizio

TITLE
Co-Founder
COMPENSATION
$3M
AGE
47
TENURE
7.4 yrs

John C. Milligan

TITLE
President
COMPENSATION
$2M
AGE
56
TENURE
7.4 yrs

Brian Bernick

TITLE
Co-Founder
COMPENSATION
$1M
AGE
50

Dan Cartwright

TITLE
CFO & Treasurer
COMPENSATION
$1M
AGE
60
TENURE
7.4 yrs

Mitchell Krassan

TITLE
Executive VP & Chief Strategy Officer
COMPENSATION
$1M
AGE
52
TENURE
7.4 yrs

Michael Donegan

TITLE
VP of Finance
COMPENSATION
$531K
AGE
50
TENURE
5.9 yrs

Jason Spitz

TITLE
Vice President of Commercial Development & Operations

Joel Krasnow

TITLE
Chief Scientific Officer and Head of Regulatory Department
TENURE
5.3 yrs

Adam Miller

TITLE
Chief Information Officer
TENURE
1 yrs

Nichol Ochsner

TITLE
Vice President of Investor Relations
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the TherapeuticsMD board of directors in years:

7.1
Average Tenure
53
Average Age
  • The tenure for the TherapeuticsMD board of directors is about average.
Board of Directors

Tommy Thompson

TITLE
Chairman of the Board
COMPENSATION
$363K
AGE
76
TENURE
6.8 yrs

Rob Finizio

TITLE
Co-Founder
COMPENSATION
$3M
AGE
47
TENURE
7.4 yrs

John C. Milligan

TITLE
President
COMPENSATION
$2M
AGE
56
TENURE
7.4 yrs

Brian Bernick

TITLE
Co-Founder
COMPENSATION
$1M
AGE
50
TENURE
7.4 yrs

Cooper Collins

TITLE
Independent Director
COMPENSATION
$249K
AGE
39
TENURE
7.1 yrs

Robert LaPenta

TITLE
Independent Director
COMPENSATION
$254K
AGE
49
TENURE
7.1 yrs

Nick Segal

TITLE
Independent Director
COMPENSATION
$230K
AGE
36
TENURE
7.1 yrs

Jules Musing

TITLE
Independent Director
COMPENSATION
$229K
AGE
71
TENURE
5.8 yrs

Angus Russell

TITLE
Independent Director
COMPENSATION
$234K
AGE
62
TENURE
4 yrs

Marty Carroll

TITLE
Independent Director
COMPENSATION
$241K
AGE
69
TENURE
4 yrs
Who owns this company?
Recent Insider Trading
  • TherapeuticsMD insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
01. Mar 19 Sell Jules Musing Individual 27. Feb 19 27. Feb 19 -17,400 $5.80 $-100,920
23. Aug 18 Buy Thomas Thompson Individual 21. Aug 18 21. Aug 18 4,000 $5.53 $22,100
X
Management checks
We assess TherapeuticsMD's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TherapeuticsMD has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Balance Sheet A Threat To Its Future?

Help shape the future of investing tools and receive a $20 prize! … Investors are always looking for growth in small-cap stocks like TherapeuticsMD, Inc. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Is TherapeuticsMD, Inc.'s (NASDAQ:TXMD) CEO Paid Enough Relative To Peers?

First, this article will compare CEO compensation with compensation at similar sized companies. … Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. … How Does Rob Finizio's Compensation Compare With Similar Sized Companies?

Simply Wall St -

How Does Investing In TherapeuticsMD, Inc. (NASDAQ:TXMD) Impact The Volatility Of Your Portfolio?

(NASDAQ:TXMD), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

TherapeuticsMD Inc's (NASDAQ:TXMD) Shift From Loss To Profit

With the latest financial year loss of -US$77m and a trailing-twelve month of -US$94m, the US$1.1b market-cap amplifies its loss by moving further away from its breakeven target. … Many investors are wondering the rate at which TXMD will turn a profit, with the big question being “when will the company breakeven?” … Below I will provide a high-level summary of the industry analysts’ expectations for TXMD

Simply Wall St -

How Should You Think About TherapeuticsMD Inc's (NASDAQ:TXMD) Risks?

The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … Not every stock is exposed to the same level of market risk.

Simply Wall St -

Where TherapeuticsMD Inc (NASDAQ:TXMD) Stands In Terms Of Earnings Growth Against Its Industry

After looking at TherapeuticsMD Inc's (NASDAQ:TXMD) latest earnings update (31 March 2018), I found it helpful to revisit the company's performance in the past couple of years and compare this against the latest numbers. … As a long-term investor I tend to focus on earnings trend, rather than a single number at one point in time. … TXMD is loss-making, with the most recent trailing twelve-month earnings of -US$80.17m (from 31 March 2018), which compared to last year has become

Simply Wall St -

Best NasdaqGS Growth Stocks

NasdaqGS:TXMD Future Profit Nov 12th 17 Grupo Financiero Galicia S.A. … LABL’s projected future profit growth is a robust 38.51%, with an underlying 85.08% growth from its revenues expected over the upcoming years. … NasdaqGS:LABL Future Profit Nov 12th 17 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.

Simply Wall St -

Company Info

Description

TherapeuticsMD, Inc. operates as a women’s health care product company in the United States. The company’s hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. In addition, it commercializes IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Details
Name: TherapeuticsMD, Inc.
TXMD
Exchange: NasdaqGS
Founded: 2008
$1,316,743,673
241,161,845
Website: http://www.therapeuticsmd.com
Address: TherapeuticsMD, Inc.
6800 Broken Sound Parkway NW,
Third Floor,
Boca Raton,
Florida, 33487,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS TXMD Common Stock Nasdaq Global Select US USD 05. Oct 2011
DB 29T Common Stock Deutsche Boerse AG DE EUR 05. Oct 2011
Number of employees
Current staff
Staff numbers
241
TherapeuticsMD employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/18 00:22
End of day share price update: 2019/03/15 00:00
Last estimates confirmation: 2019/03/15
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.